[177Lu]Lu-RM26 / Beijing Tiantan Hospital - LARVOL DELTA

Antitumor effect and well tolerance of locoregional [177Lu]Lu-RM26 radionuclide therapy in Glioblastoma Multiforme (SNMMI 2025) - "The median OS was significantly longer in the [177Lu]Lu-RM26 group (35 days) compared to saline (25 days, P<0.0001), DOTAGA-RM26 (27 days, P<0.0001), temozolomide (30.5 days, P=0.009) and [177Lu]LuCl3 groups (32 days, P=0.002). Higher GRPR expression correlates with worse glioma subtypes, such as IDH-widetype, 1p/19q-codeletion-negative, WHO grade 4 gliomas, indicating poorer survival. Orthotopic GL261Fluc+ mice carry high GRPR-positive tumor load. Intratumoral administration of 1.11 MBq [177Lu]Lu-RM26 demonstrated higher tumor retention (biological half-life time, 74.7 hours) compared to [177Lu]LuCl3 (<1 hour)."

Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • GRP-10

Antitumor effect and well tolerance of locoregional [177Lu]Lu-RM26 radionuclide therapy in Glioblastoma Multiforme (SNMMI 2025) - "The median OS was significantly longer in the [177Lu]Lu-RM26 group (35 days) compared to saline (25 days, P<0.0001), DOTAGA-RM26 (27 days, P<0.0001), temozolomide (30.5 days, P=0.009) and [177Lu]LuCl3 groups (32 days, P=0.002). Higher GRPR expression correlates with worse glioma subtypes, such as IDH-widetype, 1p/19q-codeletion-negative, WHO grade 4 gliomas, indicating poorer survival. Orthotopic GL261Fluc+ mice carry high GRPR-positive tumor load. Intratumoral administration of 1.11 MBq [177Lu]Lu-RM26 demonstrated higher tumor retention (biological half-life time, 74.7 hours) compared to [177Lu]LuCl3 (<1 hour)."

Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • GRP-10